SUI DOLOREM UPSUM QUIA 

People


MANAGEMENT TEAM

CEO: Alexei Alexandroff

Scientific Director: Andrew M Jackson (PhD)

Clinical Director: Dr Anton Alexandroff (PhD) 

Commercial Director: Julian Penne-Stuart

Operations Director: Stephen Wiggans


ADVISORY BOARD

Professor Robin Graham-Brown

 Professor Poulam M Patel  

Alexei was initially trained and did research work in the field of Plasma Physics in Moscow. Subsequently, he worked as a producer for Sat.1, NBC News and CNBC in Russia.  In 1998, he moved to the UK and completed an MSc programme in Global Market Economics at the London School of Economics. He then worked as a consultant/country economist in the office of the Chief Economist of the European Bank for Reconstruction and Development and as an EEMEA analyst at Dresdner Kleinwort Wasserstein. He continued his career working as a partner at ASI International Consulting and Intelleca.

Andrew is Associate Professor of Cancer Immunology at the University of Nottingham and has over 25 years of experience in biomedical research. Andrew undertook his PhD at Edinburgh University in 1989 and has since lead research teams at ICRF/CRUK Leeds University (UK), Duke University (USA) and Nottingham University (UK) where he presently leads the Host-Tumour Interactions Group in the Division of Cancer and Stem Cells at the School of Medicine. He was involved in the development of anti-TNF strategies for treatment of Rheumatoid Arthritis in the 1980s and in the 1990s developed the background research for number of first-in-man clinical trials of novel DNA-vaccines for Melanoma and Breast Cancer.  His academic research interests focus on the immuno-biology of malignant melanoma of the skin and in particular intracellular signalling pathways in Dendritic Cells.  Andrew is a member of the Editorial Board of the Future Medicine journal Immunotherapy and has published more than 70 peer-reviewed research papers, review articles and book chapters.

Anton is currently an Honorary Senior Lecturer at De Montfort University and Consultant Dermatologist at Skin55 Harley St. London, Cambridge Nuffield Health, Cambridge Spire Lea and Leicester Nuffield Health hospitals. He began his research career with post-graduate studies at Edinburgh University in 1991 in the field of Cancer Immunology and has since published over 40 peer-reviewed research papers and reviews, on 30 of which he is lead or senior author. He is a member of British Association of Dermatologists, American Academy of Dermatology (International Fellow), European Society for Cosmetic and Aesthetic Dermatology, British Society for Dermatological Surgery, and UK Dermatology Clinical Trials Network. Anton is a member of the Honorary Editorial Board of the journals Clinical, Cosmetic and Investigational Dermatology and Journal of Allergy & Therapy.

Julian is an experienced business development specialist who has managed multibillion transactions. 

After graduating as an economist, has devised and successfully implemented commercial initiatives for Mitsui, APV, PWC, Taylor Woodrow, Mosenergo, MMK, IBM Consulting, Landis & Gyr, DME and many other international organisations.

After leaving formal education, Steve spent 5 years in senior sales and marketing positions with large FMCG companies before leaving the UK for employment as regional development manager for the Middle East with a niche market telecommunications company (a DHL Subsidiary), pioneering the communication revolution in x400 and x25 packet switching communications in the Region. After establishing the business as one of the most profitable divisions of the group, he came back to the UK and became a founder of and key seed fund raiser for Ceravision Ltd, a world leader in the development of High Efficiency Plasma Lighting. He then went on to become a founding shareholder and director of Emdextrade Plc, a company formed to provide a web-based trading platform for buyers and sellers of trade receivables. Emdextrade was successfully launched on the London AIM market in 2001.

Robin is an Emeritus Consultant and Honorary Senior Lecturer at the University Hospitals of Leicester. He has extensive expertise in all areas of dermatology, paediatric dermatology, eczema, acne and skin cancer. He was the editor of The British Journal of Dermatology 2000-2004, President of the British Association of Dermatologists 2005-2006 and Chairman of the Department of Health Working Party on Dermatology Closer to Home 2006-2008. He is also now Honorary Secretary of the British Skin Foundation, Chairman of the Development Board of the University of Leicester, a member of the Executive Committee of the British Association of Dermatologists, and a Member of Royal Society of Medicine, and Fellow of American Academy of Dermatology.

Poulam is the Professor of Clinical Oncology and Honorary Consultant Medical Oncologist at Nottingham University Hospitals NHS Trust.  He is Chair of the EORTC Melanoma Study Group and currently serves as advisor to a number of pharmaceutical companies and clinical-studies bodies.  His research interests include the immunology of skin-cancer (malignant melanoma), novel cancer vaccines and immunotherapeutic approaches to malignancy.  He has published over 60 papers covering basic research in tumour immunology and clinical trials in a range of tumours including first-in-man phase I trials.

Copyright © 2021 X-Biocell Ltd